Allergan plans to develop novel treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases through the acquisition of Akarna Therapeutics. The acquisition has been completed for a purchase consideration of $50m.

Pursuant to the acquisition, Allergan will gain all rights to AKN-083 and a portfolio of additional development stage FXR compounds. Akarna Therapeutics will receive additional clinical, regulatory, developmental and commercialisation milestones of its drug candidate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Walvax Biotechnology, a bio-pharmaceutical vaccination product provider, has announced to sell 85% shares in Shandong Shijie Biological Technology.

Walvax Biotechnology expects to receive gross proceeds of up to $104.5m from the transaction.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now